Selling a Dental Group to Private Equity: What to Know

Key Takeaways for Dental Group Owners

• Selling a dental group to a PE-backed DSO is a high-stakes, often once-in-a-lifetime decision. Information gaps between buyers and sellers can influence outcomes more than broad market conditions.

• Buyers in 2026 often focus on normalized EBITDA, hygiene metrics, associate depth, payer mix, lease terms, and infrastructure quality when setting valuation multiples.

• Typical DSO deals deliver 60–85% of total value as cash at close, with the balance in rollover equity and earnouts that may or may not pay out over 5–7 years.

• A structured 45–60-day competitive bid process with multiple qualified buyers can produce 30–50% higher valuations than one-on-one negotiations with a single buyer.

• McLerran & Associates provides side-by-side valuations and a competitive process that aligns incentives with sellers. Schedule a free discovery call to explore how this approach could affect your outcome.

How Private Equity Buyers Evaluate Dental Groups in 2026

EBITDA, or Earnings Before Interest, Taxes, Depreciation, and Amortization, is the profit metric PE-backed DSOs commonly use to value dental groups. Buyers start with reported income, then “normalize” it by adding back above-market owner compensation, personal expenses run through the business, and one-time costs. The goal is to estimate what the practice might earn under professional management.

That normalized EBITDA number, multiplied by a negotiated multiple, produces the enterprise value, which is the headline purchase price. In 2026, PE-backed DSOs often review several specific items when evaluating a dental group:

• Normalized EBITDA and add-back documentation, where every adjustment should be defensible under buyer scrutiny. Aggressive add-backs that do not survive diligence can be a leading source of valuation disputes.

• Hygiene and recare metrics, since practices with strong hygiene recare compliance can command valuation premiums over comparable practices with weaker recare.

• Associate depth and owner dependency, because owner-doctor production above 50% of collections can trigger an EBITDA multiple reduction and heavier earnout structures.

• Payer mix, since government payer exposure above 35% of collections can suppress EBITDA multiples and narrow the buyer pool.

• Lease terms, where short remaining lease terms under 5 years can move a practice down a valuation band.

• Provider concentration, because a single provider responsible for a large share of production introduces transition risk that buyers often price into the deal.

• Trailing-twelve-month EBITDA trends, as buyers in 2026 scrutinize recent performance more closely given mid-2025 supply cost increases.

• Infrastructure and reporting quality, where documented SOPs, KPI dashboards, and clean financial reporting can reduce integration risk and support premium multiples.

The 2026 EBITDA multiple ranges by size tier, discussed below, can be shaped by these fundamentals, specialty mix, and broader market conditions rather than by a fixed table. Before reviewing those ranges, it helps to understand which type of buyer you may target, because that choice can change how valuation is framed.

Your Two Main Transition Paths: Private Buyer vs. DSO

Owners of dental groups generating $1.5M–$3M in annual revenue often face two main transition pathways. The better fit can depend on the practice’s economics and the owner’s personal and professional goals.

In a doctor-to-doctor sale, the practice is sold outright to an individual dentist. Valuation is usually expressed as a percentage of annual collections or as a multiple of seller’s discretionary earnings (SDE, which is the total economic benefit to a working owner-operator). The buyer is commonly an individual dentist using SBA financing.

The seller often works back 4–8 weeks and then exits. This path can suit practices in the $1M–$1.5M revenue range, although some well-positioned groups in the $1.5M–$3M range may also qualify.

In a DSO or private-equity affiliation, the practice is sold to a PE-backed platform. Valuation is based on a multiple of normalized EBITDA, and the deal typically includes cash at close, rollover equity in the DSO, and an earnout. The seller usually continues practicing under a multi-year employment agreement.

This path can produce materially higher enterprise values for qualifying groups. The same $2M-revenue practice can transact at a premium through a DSO buyer versus a private buyer.

Because McLerran & Associates works both pathways in roughly equal measure, the firm can produce a genuine side-by-side valuation. That comparison quantifies a practice’s worth in both markets so owners choose with fuller information rather than a guess.

Schedule a free, confidential discovery call with McLerran & Associates to receive a side-by-side comparison of both transition pathways for your specific practice.

Current EBITDA Multiples for Dental Groups in 2026

The 2026 EBITDA multiple landscape has largely normalized from the 2021–2022 peak. Multiples on larger dental deals have moderated, yet they can remain attractive for well-positioned groups. The quality and transferability of EBITDA can be some of the main factors that determine where a practice lands within any range, not just headline size.

Institutional buyers in 2026 often reference a size-tier framework such as:

• Single-location and add-on acquisitions (under $1M EBITDA): approximately 5x–7x EBITDA, often targeting independent buyers or smaller DSOs.

• Regional DSO add-ons ($1M–$3M EBITDA): approximately 7x–9x EBITDA, with the upper end more common for practices that show strong associate production, transferable patient bases, and modern infrastructure.

• Emerging platforms ($3M–$5M EBITDA): approximately 9x–11x EBITDA for groups with shared billing and management infrastructure.

• Platform-grade transactions ($5M+ EBITDA): 10x–12x or higher in select cases, usually reserved for scaled groups with management depth and a documented growth pipeline.

Specialty practices, including oral and maxillofacial surgery, orthodontics, and pediatric dentistry, can command premiums within and above these general bands. Specialty add-ons in the $1M–$3M EBITDA range sometimes trade at 7x–10x, and larger specialty platforms can reach higher.

Oral surgery has been one of the most active specialties for PE consolidation, recording a 9.1% increase in PE deal volume in 2025 while several other specialties declined.

Several factors can suppress multiples and move a practice down a valuation band. Examples include Medicaid exposure above 40% of revenue, a single provider responsible for more than 40% of production, and lease terms with fewer than 5 years remaining.

Some market observers expect dental practice valuations to compress over time from today’s 5x–9x+ EBITDA toward a more conservative 4x–6x in the years ahead. That trend makes the current window meaningful for many well-positioned sellers.

Deal Structure Basics: Cash, Equity, and Earnouts

A DSO offer usually contains several moving parts rather than a single number. Each component can carry a different level of certainty and a different tax treatment.

Cash at close is the guaranteed portion and is the only component the seller receives regardless of what happens later. TUSK Practice Sales continues to see DSO offers structured with 60–85%+ of total consideration paid as cash at close. Across deal types, the typical range often falls between 60% and 80%.

Rollover equity, often 15–40% of proceeds, means the seller reinvests a portion of their proceeds into the DSO’s parent company and becomes a minority investor in the platform. This equity usually remains illiquid until the DSO undergoes a future recapitalization or sale, commonly 5–7 years later.

Rollover equity can be worth two to three times the rolled amount or little to nothing, depending on the DSO’s performance. Equity can be held at two levels:

• JV-level (joint venture) equity, which is ownership in the individual practice entity and may generate ongoing distributions. This structure tends to offer a higher floor but a lower ceiling on upside.

• Holding-company equity, which is ownership in the DSO’s parent platform, with no distributions but the potential for a larger payout at the next recapitalization. This structure usually carries a higher ceiling and higher risk.

Earnouts, often 5–15% of proceeds, are contingent payments tied to the practice hitting financial targets such as retained EBITDA or collections over a defined period, commonly 12–36 months after closing. Earnout structures can include cliff payouts, undefined post-close overhead allocations, and revenue definitions that exclude certain services, which can make them a frequent source of post-sale disputes.

Sellers can often benefit from seeking pro-rata, or linear, payout provisions so a near-miss on a target still pays most of the earnout. McLerran & Associates models each deal structure across 3-, 5-, 7-, and 10-year horizons, including conservative recapitalization assumptions, so owners can compare estimated after-tax proceeds across scenarios instead of reacting only to a headline number.

Schedule a free, confidential discovery call with McLerran & Associates to review a multi-year cash-flow model built around your practice’s specific numbers.

Creating Competition: The 45–60-Day Bid Process

Creating genuine competition among multiple qualified buyers at the same time can be one of the most reliable ways to maximize value in a dental group sale. Dental practices taken to market through a structured multiple-buyer solicitation process have received final sale values averaging 50% above initial unsolicited offers.

McLerran & Associates runs a structured, auction-style bid process, typically over 45–60 days, among a vetted pool of well-capitalized DSO and PE buyers. The process often generates around 10 offers per listing, which are then narrowed to the top 1–3 finalists for in-person meetings. Clients typically receive the 30–50% valuation premium mentioned earlier, driven by real market tension among qualified buyers.

2026 Dental Group Sale Process: McLerran & Associates Framework

Phase	Key Activities	Typical Timeline	Outcome
1. Valuation & Preparation	CPA-led EBITDA analysis, add-back documentation, marketing deck, and virtual data room build	Weeks 1–4	Defensible, diligence-grade valuation and a go-to-market package
2. Competitive Bid Process	Confidential outreach to vetted buyer pool, NDA execution, and offer solicitation	Weeks 5–10 (45–60 days)	Approximately 10 offers from qualified buyers and no single-buyer exposure
3. Finalist Selection & LOI Negotiation	Buyer meetings, financial forecasting per finalist, and LOI negotiation on all terms	Weeks 10–14	Signed LOI with negotiated cash, equity, and earnout terms
4. Diligence to Close	Quality-of-earnings defense, advisor coordination, and closing documentation	Weeks 14–26+	Closed transaction at agreed value and an approximately 85–90% transaction rate

McLerran & Associates has completed approximately 2,000 successful practice sales, representing roughly $2 billion in closed transaction volume, with a transaction rate of about 85–90%, compared to an industry norm closer to 35–40%. Do-it-yourself close rates can run as low as 15–20%.

Schedule a free, confidential discovery call with McLerran & Associates to explore how a structured competitive process could affect the outcome for your practice.

Vetting Private Equity-Backed DSOs Before You Commit

Not all DSOs function as equal partners, and the stakes of choosing poorly can be high. As much as 40% of a DSO deal can be paid in equity, which means the buyer’s financial health can directly affect a large share of the seller’s proceeds.

That risk is not theoretical. Some PE-backed platforms have faced significant financial restructuring in recent years, and many dental practices within those platforms have recorded limited year-over-year growth. This connection is why vetting the buyer can be just as important as negotiating the multiple.

Criteria for identifying well-capitalized, well-run buyers can include:

• Platform profitability and same-store growth, which can show whether the DSO’s existing portfolio is growing organically or relying mainly on acquisitions to show revenue gains.

• PE sponsor track record, including whether the backing firm has successfully recapitalized dental platforms before and at what approximate multiples.

• Management team depth, where experienced operators with dental-specific backgrounds can reduce integration risk.

• Capitalization and debt load, since some platforms have faced restructuring events that reduced funded debt by over $1 billion, which illustrates the risk of partnering with an overleveraged buyer.

• Post-close clinical autonomy terms, defined in the Management Services Agreement (MSA). The MSA outlines the practical boundaries of autonomy. Treatment planning and clinical protocols ideally remain the dentist’s responsibility, with written policies on scheduling input, mandatory suppliers, and dispute resolution.

• Staff and patient protections, where explicit staff retention terms in the purchase agreement can carry more weight than verbal assurances.

• References from affiliated sellers, since interviewing other affiliated providers about their post-closing experience is a recommended step before entering any DSO transaction.

Red flags can include earnout structures with undefined post-close overhead allocations, equity held only at the holding-company level with no governance rights, and buyers who resist providing references from existing affiliated practices.

McLerran & Associates vets buyers like investments and has blacklisted DSOs known for poor post-close environments so those buyers do not reach the table.

Seller Checklist: Before Signing an LOI

• Has a CPA-led, normalized EBITDA analysis been completed and documented?

• Have multiple qualified buyers been solicited at the same time?

• Has the buyer’s financial health, PE sponsor, and same-store growth been independently reviewed?

• Are clinical autonomy protections written into the MSA, not just verbally promised?

• Are earnout terms structured as pro-rata (linear) rather than cliff-based?

• Has a multi-year cash-flow model been built for each finalist’s deal structure?

• Has M&A counsel been engaged before the LOI is signed?

• Have references from the buyer’s existing affiliated practices been contacted?

Balancing Price, Culture, and Long-Term Fit

The highest bidder is not always the right buyer. Owners who have spent decades building a practice, caring for patients, and supporting staff often have priorities that extend beyond the closing wire transfer.

Finding the right fit can mean identifying a buyer whose integration model, clinical philosophy, and support infrastructure align with what the seller wants for their practice after they step back. McLerran & Associates operates exclusively on the sell side and does not represent buyers, which keeps incentives aligned with the seller’s outcome rather than the transaction alone.

The firm’s quality-of-earnings defense through diligence, which involves defending the normalized EBITDA it underwrote when the buyer’s team scrutinizes the numbers, can help keep agreed values from being re-traded near the finish line.

For the largest groups, often those with roughly $2.5M or more in EBITDA, the practice can sometimes become the platform acquisition of a new DSO. In that scenario, the owner may step into a leadership role rather than affiliating as a single location. McLerran’s financial forecasting models this option alongside traditional affiliation structures so owners can see a broader range of possibilities.

Schedule a free, confidential discovery call with McLerran & Associates to discuss how to balance price with the right long-term fit for your practice, staff, and patients.

Frequently Asked Questions

What is the typical cash-at-close percentage in 2026 DSO deals?

Most DSO deals in 2026 deliver the 60–85% cash-at-close range discussed earlier, with the balance structured as rollover equity and earnouts. The exact percentage can depend on buyer type, practice size, EBITDA quality, and how the deal is negotiated. Larger platform-grade transactions with PE-backed buyers often offer higher cash-at-close percentages than smaller add-on deals with regional DSOs. Cash at close remains the only guaranteed component, since both rollover equity and earnouts carry realization risk, which is why understanding the full structure can matter as much as the headline number.

How long do sellers usually work back after closing a DSO deal?

In a DSO or private-equity affiliation, a minimum 5-year working agreement is common, although specific terms can vary by buyer and practice. Sellers who have already reduced clinical days and built strong associate coverage may be able to negotiate a shorter commitment.

In a doctor-to-doctor walk-away sale, the work-back period is usually only 4–8 weeks before the seller exits entirely. The post-close employment period is often one of the most negotiable elements of a DSO deal and should be clearly defined, including minimum schedule, compensation structure, and clinical autonomy parameters, before any letter of intent is signed.

Which specialties tend to command the highest multiples in DSO transactions?

Specialty practices, including oral and maxillofacial surgery, orthodontics, and pediatric dentistry, can command premiums above general dentistry bands at comparable EBITDA levels. Oral surgery has been particularly active, with at least 8 PE-backed platforms consolidating the specialty and deal volume growing even as some other specialties saw declines.

Multiples within any specialty are still driven by fundamentals such as associate depth, hygiene metrics, payer mix, lease terms, and the quality of normalized EBITDA. A specialty label alone does not guarantee a premium multiple. The underlying practice economics usually determine where within any range a specific deal lands.

What are the biggest risks of accepting rollover equity in a DSO deal?

Rollover equity is illiquid and typically cannot be converted to cash until the DSO completes a future recapitalization or sale, often 5–7 years after the initial transaction. Its ultimate value depends on the DSO’s financial performance, debt levels, governance structure, and exit timing, none of which the seller controls.

If the DSO underperforms, takes on excessive debt, or fails to achieve a favorable exit, the rollover equity can be worth significantly less than its stated value or nothing at all. Some platforms have faced major financial restructurings that effectively wiped out existing equity. These realities are why vetting the buyer’s capitalization, PE sponsor track record, and same-store growth can be just as important as negotiating the headline multiple.

Why does running a competitive process matter if I already have a DSO offer?

An unsolicited offer from a single DSO is set by that buyer rather than by the broader market. Without competing bids, there is little pressure on the buyer to improve terms, and the seller has limited visibility into whether the offer reflects fair market value.

Structured competitive processes, where multiple qualified buyers submit offers at the same time, can produce higher valuations and stronger terms than single-buyer negotiations. McLerran’s process often generates around 10 offers per listing. Beyond price, competition can give the seller leverage to negotiate clinical autonomy protections, earnout terms, and staff retention provisions that a single buyer may have little incentive to offer voluntarily. The 30–50% valuation lift is often just the headline benefit.

Conclusion: Shaping the Story Around Your EBITDA

A dental group sale to private equity can be a once-in-a-lifetime transaction for the seller and a routine negotiation for the buyer. The information gap between a first-time seller and a sophisticated DSO buyer is real, and it can resolve in the buyer’s favor when the seller proceeds without representation or with limited preparation.

A diligence-grade EBITDA analysis that shapes the story around profitability from the start, combined with a competitive process that creates real tension among multiple qualified buyers and a sell-side advisor whose incentives align with the seller’s outcome, can help rebalance that equation. McLerran & Associates has guided approximately 2,000 practice owners through this process with the 85–90% transaction rate mentioned earlier, a track record built on controlling the EBITDA narrative from day one.

Demand for premier dental groups remains strong. Roughly 78% of DSOs anticipate recapitalization events within 12 to 36 months, which can create urgency among buyers to acquire durable EBITDA ahead of those events. The window for well-positioned sellers appears open, although it may not remain so indefinitely.

Owners considering a dental group sale to private equity, whether now or in the future, can benefit from an early conversation. Schedule a free, confidential discovery call with McLerran & Associates to discuss your practice, your goals, and what the 2026 market may mean for your specific situation. Call (512) 900-7989, email info@dentaltransitions.com, or visit dentaltransitions.com/contact-us.